In contrast, the reprogramming degrees of the prostate-cancer-specific enhancers FOXA1 and HOXB13 are significantly reduced during the disease progression, and both of them are pre-bound to the AR-binding sites. This evidence concerns the gene AR and prostate carcinoma.